铁亡:在食道癌症中,铁亡与治疗抵抗的关键联系
Ming-Xin Tang1, Jin-Feng Chen2, Fa-Zhi Zhao3
1Department of Gastroenterology, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
细胞死亡过程铁亡是克服食道癌 (EC) 治疗耐药性的关键. 了解铁灭菌调节剂和探索纳米技术等新疗法对于有效的EC治疗至关重要.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 铁,一种依赖于铁的调节细胞死亡,涉及脂质过氧化物积累和细胞膜损伤.
- 铁死在恶性瘤,包括食道癌 (EC) 中起着重要作用,并且是治疗耐药性的治疗标.
研究的目的:
- 系统地审查目前对EC耐药性中铁亡的理解.
- 探索针对EC的新型治疗策略,以铁死为向.
主要方法:
- 在欧洲共同体对铁灭机制的文献综述.
- 对基因,蛋白质,金属离子代谢和瘤微环境因素对铁灭耐药性的分析.
- 探索新兴的治疗方法.
主要成果:
- 铁灭症越来越多地被认为是它在克服EC治疗耐药性的作用.
- 基因,蛋白质,金属离子代谢和瘤微环境因素影响了EC中的铁灭菌耐药性.
- 各种治疗策略,包括针对铁灭的药物和纳米技术,显示出有希望的结果.
结论:
- 铁化为食道癌提供了一个有前途的治疗途径.
- 通过铁灭调节克服EC耐药性仍然是一个需要进一步研究的临床挑战.
- 新的治疗策略正在开发中,以增强EC中铁亡诱导的细胞死亡.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Treatment Resistant Cancers
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Esophageal Strictures-I: Introduction
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
